Group One Trading’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-8
Closed -$591 7673
2024
Q1
$591 Sell
8
-112
-93% -$14.8K ﹤0.01% 6716
2023
Q4
$21.4K Buy
120
+112
+1,400% +$55.1K ﹤0.01% 5701
2023
Q3
$5.76K Sell
8
-1
-11% -$4.29K ﹤0.01% 6626
2023
Q2
$39.3K Sell
9
-4
-31% -$13.9K ﹤0.01% 5466
2023
Q1
$35.7K Sell
13
-83
-86% -$243K ﹤0.01% 5111
2022
Q4
$251K Buy
96
+63
+191% +$220K ﹤0.01% 3670
2022
Q3
$129K Buy
33
+26
+371% +$102K ﹤0.01% 4539
2022
Q2
$19K Buy
7
+1
+17% +$2.6K ﹤0.01% 6341
2022
Q1
$20K Sell
6
-2
-25% -$8.6K ﹤0.01% 6761
2021
Q4
$49K Sell
8
-2
-20% -$15.4K ﹤0.01% 6360
2021
Q3
$96K Sell
10
-12
-55% -$103K ﹤0.01% 5958
2021
Q2
$226K Buy
22
+20
+1,000% +$329K ﹤0.01% 5113
2021
Q1
$34K Buy
+2
New +$23.3K ﹤0.01% 6476
2016
Q2
Hold
0
-$3K 5012
2016
Q1
Hold
0
4324
2015
Q4
Hold
0
3713
2015
Q3
Hold
0
3670
2015
Q2
Hold
0
3571
2015
Q1
Hold
0
3030
2014
Q4
Hold
0
3296
2014
Q3
Hold
0
4173
2014
Q2
Hold
0
3925
2014
Q1
Hold
0
2826
2013
Q4
Hold
0
2710
2013
Q3
Hold
0
3668
2013
Q2
Hold
0
3772

Other funds holding SEEL

Group One Trading's SEEL Position: Q4 2024 in Review

Group One Trading sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2024, closing a stake of 12 shares — an estimated $45 sold.

Group One Trading first reported a position in SEEL in Q2 2021 and held it in 13 quarters. The position peaked at $2.23M in Q3 2022. 2 funds tracked by Wall St. Rank hold SEEL as of Q4 2024.

  • Group One Trading reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Group One Trading sold 12 Seelos Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $45.
  • Group One Trading first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 13 quarters.
  • Group One Trading's Seelos Therapeutics, Inc. Common Stock position peaked at $2.23M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Group One Trading's 13F filing for Q4 2024, filed 14 Feb 2025.